Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gefapixant→

Gefapixant Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1015787-98-0
Molecular formula
C14H19N5O4S
Molecular weight
353.4 g/mol
Drug class
Selective P2X3 receptor antagonistnon-opioid antitussive
Mechanism of action
Selectively antagonises ATP-gated P2X3 receptors, with some activity at P2X2/3 receptors, on airway vagal sensory C-fibres. This reduces ATP-mediated sensory-nerve activation and the urge-to-cough signalling pathway.
Indications / reported uses
  • Treatment of refractory or unexplained chronic cough in adults under the EU-authorised indication; local availability and authorisation vary by jurisdiction

Sources: EMA EPAR — Lyfnua · EMA product information (mechanism and indication) · UK SmPC — Lyfnua 45 mg · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective P2X3 receptor antagonist; non-opioid antitussive

Mechanism of action

Selectively antagonises ATP-gated P2X3 receptors, with some activity at P2X2/3 receptors, on airway vagal sensory C-fibres. This reduces ATP-mediated sensory-nerve activation and the urge-to-cough signalling pathway.

General use cases

  • Treatment of refractory or unexplained chronic cough in adults under the EU-authorised indication; local availability and authorisation vary by jurisdiction

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Gefapixant Environmental Risk Assessment (ERA) (the Gefapixant ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.